Home / Drugs / Starting with T /
indicationFor treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)
pharmacologyTositumomab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.
mechanism of actionBinds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation.
biotransformationMost likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production
half life0.8 hours (mammalian reticulocytes, in vitro)
route of eliminationElimination of Iodine-131 occurs by decay and excretion in the urine.
drug interactionsNatalizumab: The immunosuppressant, Tositumomab, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
Trastuzumab: Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.